SNDX Live signals | Maximize Profits with Getagraph.com

BUY 94563 min ago

@ $22.05

Issued: 14 Feb 2024 @ 15:38

Return: -5.67%

Previous signal: Feb 13 - 15:50

Previous signal: Sell

Return: 4.26 %

Live Chart Being Loaded With Signals

Commentary (19 Apr 2024 @ 16:00):

Stats
Today's Volume	808 911
Average Volume	1.17M
Market Cap	1.77B
EPS	$0 ( 2024-02-27 )
Next earnings date	( $0 ) 2024-05-06
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-6.98
ATR14	$0.0240 (0.12%)

Insider Trading

Date	Person	Action	Amount	type
2024-02-07	Metzger Michael A	Buy	214 500	Stock Options (Right to buy)
2024-02-07	Metzger Michael A	Buy	39 000	Common Stock
2024-02-07	Metzger Michael A	Buy	107 250	Common Stock
2024-02-07	Goldan Keith A.	Buy	70 000	Stock Options (Right to buy)
2024-02-07	Goldan Keith A.	Buy	11 700	Common Stock

INSIDER POWER
45.96
Last 97 transactions
Buy: 2 711 593 \| Sell: 1 085 664

Volume Correlation

Long: 0.40 (neutral)

Short: 0.60 (weak)

Signal:(59.128) Neutral

Syndax Pharmaceuticals Correlation

10 Most Positive Correlations
BAFN	0.824
CVCY	0.817
CIGI	0.812
FGEN	0.811
ANPC	0.803

10 Most Negative Correlations
VERX	-0.833

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Syndax Pharmaceuticals Correlation - Currency/Commodity

0.76
( moderate )

0.48
( neutral )

0.00
( neutral )

0.62
( weak )

-0.52
( weak negative )

0.61
( weak )

Syndax Pharmaceuticals Financials

Annual	2023
Revenue:	$0
Gross Profit:	$-12 000.00 (0.00 %)
EPS:	$-2.98

Q4	2023
Revenue:	$536 000
Gross Profit:	$268 000 (50.00 %)
EPS:	$-1.000

Q3	2023
Revenue:	$0
Gross Profit:	$-3 000.00 (0.00 %)
EPS:	$-0.730

Q2	2023
Revenue:	$0
Gross Profit:	$-152 000 (0.00 %)
EPS:	$-0.640

Financial Reports:

No articles found.

Syndax Pharmaceuticals

Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of MLL-rearranged (MLLr) and nucleophosmin 1 mutant acute myeloid leukemia (NPM1c AML); and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD). The company is also developing Entinostat. It also has collaborative research and development agreement with National Cancer Institute; a clinical trial agreement with Eastern Cooperative Oncology Group; and a license agreement with Kyowa Hakko Kirin Co., Ltd. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.Massachusetts.